Sugi Predict

Sugi Predict / Compounds / SCHEMBL1849332

SCHEMBL1849332

SCHEMBL1849332

O=[C]c1ccccc1Nc1ncccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 5/20 0.41
▸ PLAU P00749 4/20 0.40
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ GFER P55789 1/20 0.39
▸ F2 P00734 1/20 0.36
▸ PLG P00747 1/20 0.36
▸ PLAT P00750 1/20 0.36
▸ KLK1 P06870 1/20 0.36
▸ PRSS1 P07477 1/20 0.36
▸ EGFR P00533 1/20 0.35
▸ KDR P35968 1/20 0.34
▸ ACHE P22303 1/20 0.34
▸ HDAC3 O15379 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ TAS2R14 Q9NYV8 1/20 0.34
▸ SLC40A1 Q9NP59 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1859709 0.81 MEN1 (0.66) AURKAMEN1KMT2AMAPK10GFER
SCHEMBL3878150 0.81 KDM4E (0.33) AURKAMEN1KMT2AMAPK10GFER
SCHEMBL1856650 0.81 AURKA (0.41) AURKAPLAUMEN1KMT2AMAPK10
SCHEMBL3265738 0.79 MEN1 (0.58) AURKAPLAUMEN1KMT2AMAPK10
SCHEMBL96064 0.74 MAPT (0.50) AURKAMEN1KMT2AGFEREGFR
SCHEMBL3950995 0.69 HTT (0.56) KMT2AMAPK10GFERKDRNPC1
SCHEMBL3956226 0.69 TSHR (0.62) AURKAMEN1KMT2AHDAC3HDAC1
SCHEMBL8401982 0.69 MAPK10 (0.55) PLAUMEN1KMT2AMAPK10GFER
SCHEMBL3951907 0.69 AURKA (0.56) AURKAPLAUMEN1KMT2AMAPK10
SCHEMBL13533951 0.69 MAPT (0.56) AURKAPLAUMEN1KMT2AMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 — — US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 — — EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 — — US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 — — WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071888-A1 PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 — — EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA AURKA 320/4885PLAU 3547/4885MEN1 1461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.